Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
Executive Summary
Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.
You may also be interested in...
Eliquis Poised To Wake Up U.S. Oral Anticoagulant Market
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
Eliquis’ European Label Supports Superiority Claims
Bristol and Pfizer expect to launch novel anticoagulant Eliquis within weeks in Germany and the U.K. following approval in Europe on Nov. 20. Eliquis looks well-positioned to compete in Europe with a label reflecting superiority on safety, efficacy for stroke prevention and mortality.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.